Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2018

01-09-2018 | Epidemiology

Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case–control study of 11,412 women

Authors: Louis Jacob, Paulina Christiana Scholten, Karel Kostev, Matthias Kalder

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Login to get access

Abstract

Purpose

The goal of the present study was to analyze the impact of sleep disorders on the development of metastases in women with breast cancer followed in gynecological practices in Germany.

Methods

The study included women who were initially diagnosed with breast cancer in 262 gynecological practices in Germany between January 2000 and December 2015 (index date). Participants were followed for up to 5 years. Women diagnosed with breast cancer metastases within a period of 6 months and before the end of follow-up were matched (1:1) by age, index year, physician, type of hormonal therapy (tamoxifen or aromatase inhibitors) and follow-up time (in months) with women without metastases. Regression analyses were conducted to study the association between sleep disorders and the presence of metastases, and these regression analyses were adjusted for depression.

Results

A total of 11,412 women were included in the present study. The mean age was 59.8 years (SD 11.4 years) and most participants were between 61 and 70 years old (metastases group: 32.6%; no-metastases group: 32.3%). Sleep disorders were associated with a significant increase in the presence of breast cancer metastases in the overall population (odds ratio [OR] 1.31) and in the different age subgroups (ORs between 1.24 and 1.43).

Conclusion

A positive association was found between sleep disorders and the presence of metastases in women diagnosed with breast cancer in gynecological practices in Germany.
Literature
1.
Ghoncheh M, Pournamdar Z, Salehiniya H (2016) Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 17:43–46CrossRefPubMed
2.
Jönsson B, Wilking N (2013) Prevention and the economic burden of breast cancer, GE Healthcare
3.
Jacob L, Kostev K, Rathmann W, Kalder M (2016) Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. J Diabetes Complicat 30:1056–1059CrossRefPubMed
4.
Cappuccio FP, D’Elia L, Strazzullo P, Miller MA (2010) Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep 33:585–592CrossRefPubMedPubMedCentral
5.
Shen X, Wu Y, Zhang D (2016) Nighttime sleep duration, 24-hour sleep duration and risk of all-cause mortality among adults: a meta-analysis of prospective cohort studies. Sci Rep 6:21480CrossRefPubMedPubMedCentral
6.
Liu T-Z, Xu C, Rota M, Cai H, Zhang C, Shi M-J, Yuan R-X, Weng H, Meng X-Y, Kwong JSW, Sun X (2017) Sleep duration and risk of all-cause mortality: A flexible, non-linear, meta-regression of 40 prospective cohort studies. Sleep Med Rev 32:28–36CrossRefPubMed
7.
Carpenter JS, Elam JL, Ridner SH, Carney PH, Cherry GJ, Cucullu HL (2004) Sleep, fatigue, and depressive symptoms in breast cancer survivors and matched healthy women experiencing hot flashes. Oncol Nurs Forum 31:591–5598CrossRefPubMed
8.
Colagiuri B, Christensen S, Jensen AB, Price MA, Butow PN, Zachariae R (2011) Prevalence and predictors of sleep difficulty in a national cohort of women with primary breast cancer three to four months postsurgery. J Pain Symptom Manag 42:710–720CrossRef
9.
Girschik J, Heyworth J, Fritschi L (2013) Self-reported sleep duration, sleep quality, and breast cancer risk in a population-based case–control study. Am J Epidemiol 177:316–327CrossRefPubMed
10.
Palesh O, Aldridge-Gerry A, Ulusakarya A, Ortiz-Tudela E, Capuron L, Innominato PF (2013) Sleep disruption in breast cancer patients and survivors. J Natl Compr Cancer Netw 11:1523–1530CrossRef
11.
Vogtmann E, Levitan EB, Hale L, Shikany JM, Shah NA, Endeshaw Y, Lewis CE, Manson JE, Chlebowski RT (2013) Association between sleep and breast cancer incidence among postmenopausal women in the Women’s Health Initiative. Sleep 36:1437–1444CrossRefPubMedPubMedCentral
12.
Palesh O, Aldridge-Gerry A, Zeitzer JM, Koopman C, Neri E, Giese-Davis J, Jo B, Kraemer H, Nouriani B, Spiegel D (2014) Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep 37:837–842CrossRefPubMedPubMedCentral
13.
Fang H-F, Miao N-F, Chen C-D, Sithole T, Chung M-H (2015) Risk of cancer in patients with insomnia, parasomnia, and obstructive sleep apnea: a nationwide nested case–control study. J Cancer 6:1140–1147CrossRefPubMedPubMedCentral
14.
Lin X, Chen W, Wei F, Ying M, Wei W, Xie X (2015) Night-shift work increases morbidity of breast cancer and all-cause mortality: a meta-analysis of 16 prospective cohort studies. Sleep Med 16:1381–1387CrossRefPubMed
15.
Otte JL, Carpenter JS, Manchanda S, Rand KL, Skaar TC, Weaver M, Chernyak Y, Zhong X, Igega C, Landis C (2015) Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained? Cancer Med 4:183–200CrossRefPubMed
16.
Qian X, Brinton LA, Schairer C, Matthews CE (2015) Sleep duration and breast cancer risk in the Breast Cancer Detection Demonstration Project follow-up cohort. Br J Cancer 112:567–571CrossRefPubMed
17.
Xiao Q, Signorello LB, Brinton LA, Cohen SS, Blot WJ, Matthews CE (2016) Sleep duration and breast cancer risk among black and white women. Sleep Med 20:25–29CrossRefPubMed
18.
Soucise A, Vaughn C, Thompson CL, Millen AE, Freudenheim JL, Wactawski-Wende J, Phipps AI, Hale L, Qi L, Ochs-Balcom HM (2017) Sleep quality, duration, and breast cancer aggressiveness. Breast Cancer Res Treat 164:169–178CrossRefPubMedPubMedCentral
19.
Sen A, Opdahl S, Strand LB, Vatten LJ, Laugsand LE, Janszky I (2017) Insomnia and the Risk of Breast Cancer: the HUNT study. Psychosom Med 79:461CrossRefPubMed
20.
Trudel-Fitzgerald C, Zhou ES, Poole EM, Zhang X, Michels KB, Eliassen AH, Chen WY, Holmes MD, Tworoger SS, Schernhammer ES (2017) Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses’ Health Study. Br J Cancer 116:1239–1246CrossRefPubMedPubMedCentral
21.
22.
Kuo H-H, Chiu M-J, Liao W-C, Hwang S-L (2006) Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. J Formos Med Assoc 105:64–69CrossRefPubMed
23.
Liede A, Jerzak KJ, Hernandez RK, Wade SW, Sun P, Narod SA (2016) The incidence of bone metastasis after early-stage breast cancer in Canada. Breast Cancer Res Treat 156:587–595CrossRefPubMed
24.
Khanfir A, Lahiani F, Bouzguenda R, Ayedi I, Daoud J, Frikha M (2013) Prognostic factors and survival in metastatic breast cancer: a single institution experience. Rep Pract Oncol Radiother 18:127–132CrossRefPubMedPubMedCentral
25.
Dombrowski S, Kostev K (2017) Use of electronic medical records in the epidemiological research. Cuvillier Verlag, Göttingen
26.
Jacob L, Freyn M, Kalder M, Dinas K, Kostev K (2018) Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years. Oncotarget 9:17420–17429CrossRefPubMedPubMedCentral
27.
Chang W-P, Liu M-E, Chang W-C, Yang AC, Ku Y-C, Pai J-T, Lin Y-W, Tsai S-J (2014) Sleep apnea and the subsequent risk of breast cancer in women: a nationwide population-based cohort study. Sleep Med 15:1016–1020CrossRefPubMed
28.
29.
30.
Allan K, Berger NA, Li L, Thompson CL (2017) Short sleep duration as a contributor to racial disparities in breast cancer tumor grade. Fam Med Community Health 5:149–154CrossRef
31.
Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A, Alonso-González C (2005) Melatonin-estrogen interactions in breast cancer. J Pineal Res 38:217–222CrossRefPubMed
32.
Irwin MR (2015) Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol 66:143–172CrossRefPubMed
33.
Irwin MR, Olmstead R, Carroll JE (2016) Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry 80:40–52CrossRefPubMed
34.
Mausbach BT, Schwab RB, Irwin SA (2015) Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 152:239–246CrossRefPubMedPubMedCentral
Metadata
Title
Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case–control study of 11,412 women
Authors
Louis Jacob
Paulina Christiana Scholten
Karel Kostev
Matthias Kalder
Publication date
01-09-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4831-x

Other articles of this Issue 2/2018

Breast Cancer Research and Treatment 2/2018 Go to the issue

Clinical trial

Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system

Clinical trial

Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer

Clinical trial

Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes

Preclinical study

Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database

Clinical trial

Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study

Epidemiology

Including internal mammary lymph nodes in radiation therapy for synchronous bilateral breast cancer: an international survey of treatment technique and clinical priorities
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits